#AANAM – Type 1 Infants Using Evrysdi for 2 Years Gaining in Skills

#AANAM – Type 1 Infants Using Evrysdi for 2 Years Gaining in Skills

292177

#AANAM – Type 1 Infants Using Evrysdi for 2 Years Gaining in Skills

Evrysdi (risdiplam) continues to improve survival and to allow infants with spinal muscular atrophy (SMA) type 1 to achieve key motor milestones, according to two-year data from the second part of the FIREFISH trial. “It is encouraging to see that infants continued to improve after 12 months of treatment, with twice as many of those who received Evrysdi for two years able to sit without support for at least five seconds,” Basil Darras, MD, a trial investigator and director of…

You must be logged in to read/download the full post.